What is the therapeutic window between GCS inhibition efficacy and systemic toxicity in GBA-PD patients?
PARTIALLY ADDRESSED
The debate identified systemic toxicity as a major concern for glucosylceramide synthase inhibitors, but no dose-response data exists for PD patients. This critical safety gap must be resolved before clinical translation of substrate reduction therapy.
Source: Debate session sess_sda-2026-04-01-002 (Analysis: sda-2026-04-01-002)
Landscape Summary:
What is the therapeutic window between GCS inhibition efficacy and systemic toxicity in GBA-PD patients? is a 0.9 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
What is the therapeutic window between GCS inhibition efficacy and systemic toxicity in GBA-PD patients? — INVOKE-2 (completed)